Subject(s)
Diaphragm/physiopathology , Guillain-Barre Syndrome/physiopathology , Paralysis/physiopathology , Respiratory Insufficiency/physiopathology , Diaphragm/pathology , Female , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/pathology , Guillain-Barre Syndrome/therapy , Humans , Middle Aged , Paralysis/etiology , Paralysis/pathology , Paralysis/therapy , Respiratory Insufficiency/etiology , Respiratory Insufficiency/pathology , Respiratory Insufficiency/therapyABSTRACT
Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). The aim of this work was to evaluate the efficacy of lenalidomide in patients with MF treated within a named patient program in Austria. A total of 22 patients with MF were treated with lenalidomide in 7 different centres throughout Austria. Median age of patients was 68 years. Primary MF was present in 13 patients. Eight patients had post-polycythemia vera (post-PV) and 1 post-essential thrombocythemia (post-ET) MF. According to the Dynamic International Prognostic Scoring System (DIPSS), all patients were scored within the intermediate-2 or high-risk group. Approximately one-third of patients were treated with 2 or more prior therapies. The overall response rate according to International Working Group (IWG) criteria was 12.5 %. Efficacy of lenalidomide was moderate in this non-study patient population. Limiting factors seemed to be stage of disease and risk profile of patients included in this analysis.
Subject(s)
Anemia/chemically induced , Leukopenia/chemically induced , Primary Myelofibrosis/complications , Primary Myelofibrosis/drug therapy , Thalidomide/analogs & derivatives , Thrombocytopenia/chemically induced , Aged , Aged, 80 and over , Austria , Dose-Response Relationship, Drug , Female , Humans , Immunologic Factors , Lenalidomide , Male , Middle Aged , Primary Myelofibrosis/diagnosis , Thalidomide/administration & dosage , Thalidomide/adverse effects , Thrombocytopenia/diagnosis , Treatment OutcomeABSTRACT
Myeloid sarcomas are rare manifestations of mainly myeloblastic leukemia. Their occurrence in the central nervous system is exceptional and current literature is limited to case studies. A case is added herewith and a review was performed to investigate clinical characteristics and treatment options of central nervous system myeloid sarcoma. A 61-year-old female with acute myeloblastic leukemia (FAB M5) and progressive left sided hemiparesis showed a right parieto-occipital epidural lesion mimicking meningioma. Partial resection was performed to reveal a myeloid sarcoma. Reviewing the literature we identified 44 cases with sufficient description of the diagnosis, treatment and follow up to one year. In these patients different treatment regimens were applied. However, when systemic chemotherapy or irradiation was included in the treatment regimen, patients showed the best 1-year survival proportion.
